Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Journal of Allergy and Clinical Immunology · 2026-01 · 157 (1) · 143-154
DOI: 10.1016/j.jaci.2025.09.028 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-01. Verfasst von Ana Maria Giménez-Arnau und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: anamariagimenezar…. Hauptthemen laut MEDLINE: Chronic Urticaria, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
BACKGROUND: Remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, demonstrated significant improvements in disease activity over placebo in the 24-week phase 3 REMIX studies in patients with chronic spontaneous urticaria (CSU) remaining symptomatic despite second-generation H1-antihistamines. OBJECTIVE: We sought to evaluate the long-term efficacy and safety of remibrutinib in patients with CSU. METHODS: REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were two randomized placebo-controlled studies evaluating the efficacy, safety, and tolerability of remibrutinib in patients with CSU. Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks). The primary end point was change from baseline in weekly Urticaria Activity Score at week 12. RESULTS: A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive remibrutinib (n = 313 and 300, respectively) or placebo (n = 157 and 155, respectively). At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning). Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis. CONCLUSION: Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H1-antihistamines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain. Electronic address: anamariagimenezarnau@gmail.com.
- Allergy, Asthma, and Immunology Associates PC, Lincoln, Neb.
- Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Canada; Allergy Research Canada, Niagra Falls, Canada; Probity Medical Research, Waterloo, Canada.
- Department of Dermatology, Polyclinique Saint George, Groupe KANTYS, Nice, France.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
Förderung
- Novartis
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Giménez-Arnau, A. M., Szalewski, R., Hide, M., Jain, V., Khemis, A., Lebwohl, M., Metz, M., Mosnaim, G., Palumbo, M., Şavk, E., Sussman, G., Walecka-Herniczek, I., Yang, B., Field, C., Haemmerle, S., Lheritier, K., Machado, P. G. P., Martzloff, E. D., Seko, N., …, & Saini, S. (2026). Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. Journal of Allergy and Clinical Immunology, 157(1), 143-154. https://doi.org/10.1016/j.jaci.2025.09.028
Vancouver
Giménez-Arnau AM, Szalewski R, Hide M, Jain V, Khemis A, Lebwohl M, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. Journal of Allergy and Clinical Immunology. 2026;157(1):143-154. doi:10.1016/j.jaci.2025.09.028
BibTeX
@article{GimnezArnau2026,
author = {Giménez-Arnau, Ana Maria and Szalewski, Robert and Hide, Michihiro and Jain, Vipul and Khemis, Abdallah and Lebwohl, Mark and Metz, Martin and Mosnaim, Giselle and Palumbo, Michael and Şavk, Ekin and Sussman, Gordon and Walecka-Herniczek, Irena and Yang, Bin and Field, Claire and Haemmerle, Sibylle and Lheritier, Karine and Machado, Paula G P and Martzloff, El-Djouher and Seko, Noriko and Wang, Pengpeng and Zharkov, Artem and Saini, Sarbjit},
title = {Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {157},
number = {1},
pages = {143--154},
doi = {10.1016/j.jaci.2025.09.028}
}
EUVIMED